文献速递核素与放射性配体治疗放射性药物与辐射防护

儿童神经母细胞瘤患者接受镥-177-DOTATATE治疗时患者及他人的辐射暴露

Radiation Exposure to Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-DOTATATE.
PubMed 文献 · Clin Nucl Med · 2025-02-25

研究纳入23例3–13岁神经母细胞瘤患儿,评估镥-177-DOTATATE清除率及患者、家庭照护者和医护人员的有效剂量。给药后1–96小时全身滞留率从72.0%降至10.0%,预计11天内99%清除;1米和2米处11天内最大累积有效剂量分别为0.442±0.174和0.138±0.058 mSv;家庭照护者全身有效剂量平均0.245±0.063 mSv;作者结论为患儿体内镥-177-DOTATATE清除迅速,他人所受辐射暴露低于个人剂量限值。

要点

  • 患儿给药后1–96小时全身滞留率72.0%–10.0%,预计11天内99%清除。
  • 1米和2米处11天内最大累积有效剂量分别为0.442±0.174和0.138±0.058 mSv。
  • 家庭照护者全身有效剂量平均0.245±0.063 mSv,低于个人剂量限值。

核心结论

  • 镥-177-DOTATATE在神经母细胞瘤患儿体内清除迅速,他人所受辐射暴露低于个人剂量限值。

研究设计与样本

  • 纳入2023年至2024年间接受镥-177-DOTATATE治疗的23例3–13岁神经母细胞瘤患儿。
  • 给药后0、1、2、4、6、24、48和96小时测量外部剂量率,估算患儿镥-177-DOTATATE滞留率、有效半衰期及周围最大累积有效剂量。
  • 基于多时间点全身平面显像和SPECT/CT显像,使用HERMES剂量学软件计算全身和红骨髓吸收剂量。
  • 使用热释光剂量计测量家庭照护者和医护人员的全身有效剂量,使用戒指热释光剂量计测量医护人员手指有效剂量。

主要发现

  • 平均给药活度为3.687±1.545(范围1.469–7.368)GBq。
  • 给药后1–96小时全身滞留率为72.0%至10.0%,预计11天内99%清除。
  • 清除符合双指数衰减模型,2米处快相和慢相有效半衰期分别为1.4±0.8和52.3±18.6小时。
  • 1米和2米处11天内估算最大累积有效剂量分别为0.442±0.174和0.138±0.058 mSv。
  • 患儿全身吸收剂量为0.159±0.076 mGy/MBq,红骨髓吸收剂量为0.611±0.416 mGy/MBq;家庭照护者全身有效剂量平均0.245±0.063(范围0.150–0.390)mSv;放射药师全身和手指有效剂量分别为3.7±1.8和155.3±73.0 μSv/患者;护士全身有效剂量平均4.7±1.4 μSv/患者,手指有效剂量中位数(P25,P75)为16.7(10,470)μSv/患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluated Lutetium-177-(DOTA°,Tyr 3 ) octreotate (Lu-177-DOTATATE) clearance in pediatric patients with neuroblastoma and assessed the effective doses received by patients, family caregivers, and medical staff during therapy. PATIENTS AND METHODS: Twenty-three children (3-13 y) who received Lu-177-DOTATATE between 2023 and 2024 were enrolled. External dose rates were measured at 0, 1, 2, 4, 6, 24, 48, and 96 hours post-administration to estimate patients' Lu-177-DOTATATE retention rate, the effective half-life, and the maximum cumulative effective dose around patients. Whole-body and red-marrow absorbed doses were calculated based on multi-time-point whole-body planar and SPECT/CT imaging using HERMES Dosimetry software. Whole-body effective doses to family caregivers and medical personnel were measured using thermoluminescence dosimeters (TLDs), and effective finger doses for medical staff were measured using ring TLDs. RESULTS: The mean administered activity was 3.687±1.545 (range, 1.469-7.368) GBq. Whole-body retention rates at 1-96 hours post-administration ranged from 72.0% to 10.0%, with 99% clearance expected within 11 days. Clearance followed a biexponential decay model, with estimated effective half-lives of 1.4±0.8 and 52.3±18.6 hours for the fast and slow phases, respectively, at 2 m. Estimated maximum cumulative effective doses (within 11 days) at 1 and 2 m were 0.442±0.174 and 0.138±0.058 mSv, respectively. Absorbed doses for children were 0.159±0.076 mGy/MBq (whole body) and 0.611±0.416 mGy/MBq (red-marrow). Whole-body effective doses to family caregivers averaged 0.245±0.063 (range, 0.150-0.390) mSv. The whole-body and finger-effective doses to the radiopharmacists were 3.7±1.8 and 155.3±73.0 μSv/patient, respectively. The mean of whole-body and the median ( P25 , P75 ) of finger-effective doses to nurses were 4.7±1.4 μSv/patient and 16.7 (10, 470) μSv/patient, respectively. CONCLUSIONS: Lu-177-DOTATATE was rapidly cleared in children with neuroblastoma. Radiation exposure to others was below personal dose limits.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lu Z, Sun Y, Zuo D, et al. Radiation Exposure to Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-DOTATATE. Clin Nucl Med. 2025. PMID: 39992800. doi:10.1097/RLU.0000000000005763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。